Skip to main content

Table 1 Characteristics of CMV replicating and non-replicating kidney transplant patients.

From: Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients

  CMV D+R- CMV D+R+/D-R+
Initial CMV replication all yes no all yes no
numbera 25 9 16 48 6 42
Age, median years (range) 60 (18–71) 63 (25–71) 59 (18–71) 49 (21–73) 53 (43–70) 43 (21–73)
Gender (m/f) 15/10 6/3 9/7 33/15 5/1 28/14
Sample date, weeks postTx median (range) 18 (2–383) 30 (6–41) 15 (2–383) 27 (2–314) 21 (5–138) 17 (2–314)
Induction (%) 19 (76.0%) 7 (77.8%) 12 (54.5%) 36 (75.0%) 3 (50.0%) 33 (76.7%)
T-cell depleting induction (%) 1 (4.0%) 0 (0.0%) 1 (4.5%) 4 (8.3%) 0 (0.0%) 4 (9.3%)
AR therapy (%) 8 (32.0%) 2 (22.2%) 6 (27.3%) 21 (43.8%) 3 (50.0%) 18 (41.9%)
T-cell depleting AR therapy (%) 3 (12.0%) 0 (0.0%) 3 (13.6%) 11 (22.9%) 2 (33.3%) 9 (20.9%)
Initial CMV load, mean (c/ml)a - 109'900 < 300 - 49'588 < 300
Initial CMV peak, mean (c/ml) - 181'811 < 300 - 90'009 < 300
Later CMV replication (n/total)b - 1/9 5/16 - 1/6 7/42
Later CMV load, mean (c/ml) - 288'001 9'323 - 1'489 72'581
Later CMV peak, mean (c/ml) - 1'240'000 37'260 - 3'387 311'071
  1. Note. Cytomegalovirus (CMV) seronegative KT patients had a D+R- serostatus. CMV seropositive KT patients were D+R+ or D-R+. AR, acute rejection; ATG, anti-thymoglobuline.
  2. a Patients are grouped according to CMV replication at initial time-point of testing PCR and T-cell responses and denoted as initial CMV episode.
  3. b Positive PCR testing detected during follow-up was denoted as later CMV episode.